Skip to main content

May 2020

 

Clinical courses

Job for B.Pharm, M.Pharm in Quality Assurance, Production at Mankind Pharma

Mankind Pharma, the 7th largest Pharmaceutical Company of India, was incepted in 1995 with a meagre capital of 50 lakhs and 20 employees. Today, we are amongst the top 5 fastest growing Pharmaceutical companies of India with an employee base of more than 10000 and heading towards a turnover of  INR 3000 crores.

Vacancy for Pharmacists (05 posts) at Aviva Pharmatech Private Limited

Aviva Pharmatech Private Limited is a Private incorporated on 30 April 2015. It is classified as Non-govt company and is registered at Registrar of Companies, Mumbai. Its authorized share capital is Rs. 2,000,000 and its paid up capital is Rs. 100,000. It is inolved in Manufacture of other chemical products  Aviva Pharmatech Private Limited's Annual General Meeting (AGM) was last held on 30 September 2019 and as per records from Ministry of Corporate Affairs (MCA), its balance sheet was last filed on 31 March 2019.

Post : Pharmacist

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Chlorzoxazone Tablets USP, 375 mg and 750 mg. This marks Glenmark’s first ANDA approval out of their new North American manufacturing facility based in Monroe, North Carolina.

According to IQVIATM,1 sales data for the 12 month period ending March 2020, the Chlorzoxazone Tablets, 375 mg and 750 mg market2 achieved annual sales of approximately $20.9 million*. Glenmark’s current portfolio consists of 163 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the U.S. FDA.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

<< Back to Pharma News


Subscribe to PharmaTutor News Alerts by Email

Biocon Ltd an innovation-led global biopharmaceuticals company, announced that its subsidiary Biocon Biologics has received the Drugs Controller General of India’s (DCGI) approval for an extracorporeal blood purification (EBP) device CytoSorb® to reduce pro-inflammatory cytokines levels in confirmed COVID-19 patients admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure.

Biocon Biologics has been granted licence for emergency use of CytoSorb in public interest by the Indian health regulator to treat COVID-19 patients who are 18 years of age or older. The licence will be effective until control of the COVID-19 outbreak in the country.

Studies have shown that COVID-19 patients who develop serious complications experience a ‘cytokine storm,’ also known as Cytokine Release Syndrome (CRS), which leads to excessive inflammation, organ failure and death. The goal of CytoSorb therapy is to reduce cytokine storm and the deadly inflammatory response through blood purification so that this injury may be mitigated or prevented.

The Company has received approval from DCGI in Form MD-15 (Medical Device) for reducing pro-inflammatory cytokine levels in order to control the ‘cytokine storm’ and benefit COVID-19 patients who are in a critical condition.


Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said: “As a science-led organization, Biocon’s endeavour is to provide innovative solutions to patients to address their unmet needs. CytoSorb is an in-licensed unique device that reduces cytokine storm in critically ill patients and was introduced by Biocon in India in 2013.

Since then many patients undergoing organ transplant and sepsis treatment have benefitted from it.  DCGI approval for emergency use of CytoSorb for critical COVID-19 patients is an important example of how industry and regulators are working in tandem to urgently provide physicians and patients with new treatment options in the fight against COVID-19. CytoSorb will be an important addition to the Indian medical community’s arsenal against the deadly coronavirus.”


With more than 80,000* documented active coronavirus infections and over 4,000* deaths, India needs new therapies to reduce the severity of this disease.

CytoSorb is plug-and-play compatible with the most commonly used blood purification machines or pumps in the ICU used to treat COVID-19 patients, including hemoperfusion, hemodialysis, continuous renal replacement therapy (CRRT), and extracorporeal membrane oxygenation (ECMO) machines.

In April, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of CytoSorb for use in patients with COVID-19 infection.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email

 

Walk in interview for M.Pharm, B.Pharm, M.Sc in QA, QC, Production, Packing at Indoco Remedies Ltd

Indoco Remedies Limited is a fully integrated, research-oriented Pharma Company with presence in 55 countries. A Leading Indian Pharma Company with Global Presence and approvals from various Regulatory Authorities like, USFDA, UKMHRA, TGA-Australia, etc.

Recruitment for Pharmacists (06 posts) at BNCMC | Government Jobs

In order to prevent the spread of Corona Virus (Covid-19), to work in Bhiwandi Nizampur Municipal Corporation as Pharmacist.

Post : Pharmacist

Vacancy for Pharmacist at Shri Chhatrapati Shivaji Maharaj Sarvopchar Rugnalay

This prestigious institute was founded in 1963 by Dr. Vishnu Ganesh Vaishampayan. The Undergraduate MCI recognition for MBBS Courses was obtained in 1974. Initially a private medical college,it was overtaken by government in 1977. MCI recognition for post graduate courses was obtained in 1977.The progress of the college continues till today and now it’s one of the most recognized college for Undergraduate and postgraduate medical education in India. This college is attached to Shri Chhatrapati Shivaji Maharaj Sarvopchar Rugnalaya.(Civil Hospital) with Hospital bed strength of 733.

Post : Pharmacist

Walk in interview for Tablet Manufacturing & Packing at UMEDICA Laboratories

UMEDICA is a part of the Amoli Group of Companies, manufacturing and exporting a wide range of formulations viz; Injectables, Tablets, Capsules, Suspensions, Dry Syrups, etc. UMEDICA offers a diverse product portfolio comprising of antibiotics, non-steroidal anti-inflammatory (NSAIDs), analgesics, antifungal, antiviral, anti-malarials, antituberculosis agents, antihistaminics, psychotropic, antihypertensives, lipid-lowering agents, drugs for sexual dysfunction, multivitamins etc.